Ondansetron

All congenital malformations (majors, minors, majors and minors, or unspecified)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S3471
R11257
Bérard, 2019 Major malformations 1st trimester population based cohort propective unexposed (general population or NOS) Adjustment: Yes 0.57 [0.13;2.49] 2/31   14,402/179,106 14,404 31
ref
S3852
R11260
Huybrechts, 2019 Congenital malformations 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes Intravenous 1.02 [0.96;1.08] -/23,866   -/1,762,018 - 23,866
ref
S2852
R11261
Huybrechts (Control exposed to other treatment), 2018 Any congenital malformations 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 1.00 [0.95;1.05]
excluded (control group)
2,067/55,579   6,137/185,699 8,204 55,579
ref
S2844
R11262
Huybrechts (Unexposed control), 2018 Any congenital malformations 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.01 [0.98;1.05] 3,275/88,446   54,163/1,727,546 57,438 88,446
ref
S2778
R3782
Fejzo (Mainly exposed to other treatements, sick), 2016 Birth Defects (major and minor) 1st trimester retrospective cohort exposed to other treatment, sick excluded Adjustment: No 1.02 [0.55;1.90] C
excluded (control group)
33/952   15/441 48 952
ref
S2776
R3744
Fejzo (Unexposed control, disease free), 2016 Birth Defects (major and minor) 1st trimester retrospective cohort unexposed, disease free Adjustment: No 1.89 [1.11;3.22] C 33/952   24/1,286 57 952
ref
S2856
R3995
Shahraki, 2016 Congenital anomaly during pregnancy (anytime or not specified) excluded randomized controlled trial exposed to other treatment, sick Adjustment: Randomisation 1.14 [0.02;57.92] C
excluded (exposition period)
0/88   0/100 0 88
ref
S2752
R3659
Danielsson, 2014 Any malformation early pregnancy population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 0.95 [0.72;1.26] 49/1,349   64,215/1,501,434 64,264 1,349
ref
S3184
R5102
Ozdemirci, 2014 Fetal anomaly 1st trimester retrospective cohort exposed to other treatment, sick Adjustment: No 0.20 [0.02;1.87] C 1/100   4/85 5 100
ref
S2753
R11255
Andersen, 2013 Major congenital malformations 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.30 [1.00;1.70] 58/1,248   31,357/895,770 31,415 1,248
ref
S2775
R3722
Colvin, 2013 Any birth defect during pregnancy (anytime or not specified) excluded retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.30 [0.80;2.10]
excluded (exposition period)
16/263   4,749/98,062 4,765 263
ref
S2755
R11258
Einarson (Control exposed to other antiemetics), 2004 Major malformations 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 1.93 [0.47;7.84] C
excluded (control group)
6/169   3/160 9 169
ref
S2754
R11259
Einarson (Unexposed control), 2004 Major malformations 1st trimester prospective cohort unexposed, disease free Adjustment: No 1.95 [0.48;7.94] C 6/169   3/162 9 169
ref
Total 8 studies 1.04 [0.96;1.12] 167,592 116,161
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bérard, 2019Bérard, 2019 0.57[0.13; 2.49]14,404310%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Huybrechts, 2019Huybrechts, 2019 1.02[0.96; 1.08]-23,86639%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Huybrechts (Unexposed control), 2018Huybrechts, 2018 1 1.01[0.98; 1.05]57,43888,44646%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Fejzo (Unexposed control, disease free), 2016Fejzo, 2016 2 1.89[1.11; 3.22]579522%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Danielsson, 2014Danielsson, 2014 0.95[0.72; 1.26]64,2641,3496%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: unclearROB reporting: moderate Ozdemirci, 2014Ozdemirci, 2014 0.20[0.02; 1.87]51000%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Andersen, 2013Andersen, 2013 1.30[1.00; 1.70]31,4151,2487%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Einarson (Unexposed control), 2004Einarson, 2004 3 1.95[0.48; 7.94]91690%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (8 studies) I2 = 43% 1.04[0.96; 1.12]167,592116,1610.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Unexposed control; 2: Unexposed control, disease free; 3: Unexposed control;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.04[0.96; 1.12]167,592116,16143%moderateBérard, 2019 Huybrechts, 2019 Huybrechts (Unexposed control), 2018 Fejzo (Unexposed control, disease free), 2016 Danielsson, 2014 Ozdemirci, 2014 Andersen, 2013 Einarson (Unexposed control), 2004 8 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.04[0.97; 1.11]167,587116,06142%moderateBérard, 2019 Huybrechts, 2019 Huybrechts (Unexposed control), 2018 Fejzo (Unexposed control, disease free), 2016 Danielsson, 2014 Andersen, 2013 Einarson (Unexposed control), 2004 7 exposed to other treatment, sickexposed to other treatment, sick 0.20[0.02; 1.87]5100 -moderateOzdemirci, 2014 1 Tags Adjustment   - No  - No 1.36[0.52; 3.61]711,22146%moderateFejzo (Unexposed control, disease free), 2016 Ozdemirci, 2014 Einarson (Unexposed control), 2004 3   - Yes  - Yes 1.02[0.98; 1.05]167,521114,9406%moderateBérard, 2019 Huybrechts, 2019 Huybrechts (Unexposed control), 2018 Danielsson, 2014 Andersen, 2013 5 IntravenousIntravenous 1.02[0.96; 1.08]-23,866 -moderateHuybrechts, 2019 1 All studiesAll studies 1.04[0.96; 1.12]167,592116,16143%moderateBérard, 2019 Huybrechts, 2019 Huybrechts (Unexposed control), 2018 Fejzo (Unexposed control, disease free), 2016 Danielsson, 2014 Ozdemirci, 2014 Andersen, 2013 Einarson (Unexposed control), 2004 80.15.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-2.72.71.3540.000Bérard, 2019Huybrechts, 2019Huybrechts (Unexposed control), 2018Fejzo (Unexposed control, disease free), 2016Danielsson, 2014Ozdemirci, 2014Andersen, 2013Einarson (Unexposed control), 2004

Asymetry test p-value = 0.5341 (by Egger's regression)

slope=0.0065 (0.0257); intercept=0.4000 (0.6066); t=0.6594; p=0.5341

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 2755, 2778, 2852

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.04[0.97; 1.11]167,587116,06142%NABérard, 2019 Huybrechts, 2019 Huybrechts (Unexposed control), 2018 Fejzo (Unexposed control, disease free), 2016 Danielsson, 2014 Andersen, 2013 Einarson (Unexposed control), 2004 7 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.00[0.95; 1.05]8,26656,8000%NAHuybrechts (Control exposed to other treatment), 2018 Fejzo (Mainly exposed to other treatements, sick), 2016 Ozdemirci, 2014 Einarson (Control exposed to other antiemetics), 2004 40.510.01.0